Staked financially by some of the best-known firms in life sciences, like GlaxoSmithKline and Kleiner Perkins Caufield and Byers, and intellectually by top-notch research from Harvard University, South San Francisco-based iPierian looked to ride a wave of drugs built around induced pluripotent stem cell technology.
No comments:
Post a Comment